Download Daniel C. Chung - of RP Fighting Blindness

CV of Invited Speaker
Daniel C. CHUNG
Position:
Clinical Ophthalmic Lead
Organization:
Spark Therapeutics, Inc.
Major Field:
Ophthalmology, Gene
Education:
1981-85
B.S. Eastern Nazarene College, Quincy, MA (Biology)
1988-88
M.A. Eastern Nazarene College, Quincy, MA (Family Counseling)
1990-94
D.O. New York College of Osteopathic Medicine, Westbury, NY
(Medicine)
Postgraduate Training and Fellowship Appointments:
1985-88
Research Assistant, Brigham and Women’s Hospital/Harvard
Medical School, Boston, MA.
1988-90
Research Biologist, U.S. Dept. of Defense, Bethesda, MD.
1994-97
Fellow, Ocular Gene Therapy Section, Laboratory of Immunology,
National Eye Institute/NIH, Bethesda, MD.
1997-98
Transitional Intern, Summa Health Systems, Akron, OH (ACGME
accredited)
1998-01
Ophthalmology Resident, Summa Health Systems, Akron, OH
(ACGME accredited)
2000-01
Profession Experiences:
Chief Resident, Dept. of Ophthalmology, Summa Health Systems,
Akron, OH.
2001-03
Fellow, Pediatric Ophthalmology, Cole Eye Institute, Cleveland
Clinic Foundation, Cleveland, OH
2001-03
Research Fellow, Ophthalmic Genetics, Cole Eye Institute,
Cleveland Clinic Foundation, Cleveland, OH
Appointments:
2006-2010Instructor of Ophthalmology, Scheie Eye Institute, Department of
Ophthalmology University of Pennsylvania School of Medicine
2008-2014Scientific Advisor, Leber Congenital Amaurosis Gene Therapy
Clinical Trial Team Phase 1/3, The Children’s Hospital of Philadelphia.
2010-2014Senior
Investigator,
FM
Kirby
Center
for
Molecular
Ophthalmology, Scheie Eye Institute, Department of Ophthalmology
University of Pennsylvania School of Medicine
2014-2016Medical Affairs Ophthalmic Lead, Spark Therapeutics, Inc,
Philadelphia, PA Global ophthalmic disease lead
2016-Clinical Ophthalmic Lead, Spark Therapeutics, Inc, Philadelphia, PA
Global ophthalmic disease lead
Honors & Awards:
Dr. Chung is the Ophthalmic Lead for Spark Therapeutics. Prior to joining
Spark Therapeutics, he was a senior investigator at the FM Kirby Center for
Molecular Ophthalmology at the Scheie Eye Institute at the Perelman
School of Medicine of the University of Pennsylvania, working in retinal
gene therapy and transfer. Concurrently, he served as the scientific advisor
on the RPE65 gene therapy study team at the Children’s Hospital of
Philadelphia (CHOP). Dr. Chung earned his medical degree from the New
Short Bio:
York Institute of Technology College of Osteopathic Medicine and
completed his residency in Akron, Ohio. He then completed fellowships in
pediatric ophthalmology and ocular genetics research at the Cole Eye
Institute at the Cleveland Clinic, with additional training in retinal gene
therapy at the National Eye Institute in Bethesda, MD. In his current duties,
he continues to be connected to the RPE65 gene therapy trial, as Spark
Therapeutics is now the sponsor. As the global clinical ophthalmic lead, he
works in the areas of medical affairs, clinical development and operations,
and research and development.
Abstract of Invited Speaker
Title:
Developing Patient Relevant Outcomes in Gene Therapy Trials
Currently accepted endpoints for ophthalmic interventions are visual
acuity loss and visual fields; however these endpoints of visual function
may not accurately assess the functional vision of patients with inherited
retinal dystrophies (IRD) or the benefits received from potential
pharmacologic interventions. Therefore, endpoints that focus more on
functional vision outcomes are being developed. Functional vision is
defined as the vision that is required for the ability to conduct activities of
daily living, and encompass aspects of light sensitivity, visual acuity, visual
field and contrast sensitivity. Regulatory groups are also advocating
endpoints that reflect improvements in the quality of life. Recent gene
Abstract:
therapy clinical trials using gene therapy for individuals with inherited
retinal disease due to autosomal-recessive RPE65 gene mutations have
developed
a
novel
multi-luminance
mobility
course
aimed
at
demonstrating changes in functional vision. This mobility course
represents every day challenges faced by these and other IRD patients by
requiring them to use their functional vision to follow a path and avoid
obstacles. This population also suffers from nyctalopia, night blindness,
and by administering the test at a number of different light levels, any
changes in low light vision can be evaluated. The test was refined and
standardized for use in the pivotal Phase 3 trial and Multi-luminance
Mobility Testing Study was performed to confirm test construct and
testing validity.